OKYO Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
OKYO Pharma Ltd., a foreign private issuer reporting on Form 20-F, furnished this Form 6-K on May 11, 2023. The filing concerns the timing of the company’s planned delisting from the standard segment of the FCA Official List and from trading on the London Stock Exchange Main Market.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Material Change Versus Prior Period
The company delayed the effective date of the delisting from its previously announced timing to Monday, May 22, 2023. The stated reason was to facilitate late transfers of certificated positions into CREST before the delisting.
Guidance, Outlook, Risks, and Unusual Items
- The ordinary shares were scheduled to be cancelled from listing on the FCA Official List and from trading on the LSE Main Market on May 22, 2023.
- The filing does not provide operating guidance, financial outlook, risk-factor updates, contingencies, or clinical-development updates.
- Exhibit 99.1 contains the related company announcement. The exhibit was furnished rather than filed and is not subject to Section 18 liability or incorporated by reference unless expressly stated in another filing.
Investor Verification Items
- Verify that the delisting occurred on May 22, 2023, and review any subsequent announcements regarding trading, shareholder liquidity, or alternative listing arrangements.
- Confirm the status of certificated share transfers into CREST and any unresolved shareholder positions.
- Review the company’s latest Form 20-F and subsequent filings for financial condition, funding requirements, and business developments, which are not addressed in this Form 6-K.